Creatine Supplementation on Fatigue Related to Post-COVID-19 Condition—Fatigue Study: A Randomized Controlled Trial

Why It Matters

If confirmed, creatine could become a low‑cost, easily accessible adjunct therapy for the millions suffering persistent fatigue after COVID‑19, reducing healthcare burden and improving quality of life.

Key Takeaways

• 6 g/day creatine reduced fatigue scores significantly
• Hand‑grip strength increased by over 4 kg in creatine group
• Higher 18 g dose showed no fatigue improvement
• Gastrointestinal side effects were dose‑dependent but mild
• Study limited by small sample and short duration

Pulse Analysis

Creatine’s role in cellular energy metabolism has long been recognized in sports and clinical nutrition, but its application to post‑COVID‑19 condition (PCC) is novel. The trial’s findings align with emerging evidence that mitochondrial dysfunction and depleted phosphocreatine stores contribute to the chronic fatigue seen in long‑COVID patients. By replenishing the intramuscular creatine pool, a modest 6 g daily dose appears to restore rapid ATP regeneration during brief, high‑intensity efforts, translating into measurable improvements in patient‑reported fatigue and hand‑grip strength. This mechanistic insight supports a biologically plausible pathway for symptom relief, differentiating creatine from generic supplements that lack targeted metabolic effects.

Beyond the primary outcomes, the study highlights practical considerations for integrating creatine into PCC management. The supplementation was paired with a structured rehabilitation program, suggesting synergistic benefits when combined with exercise‑induced mitochondrial biogenesis. Although the 18 g dose failed to show added advantage and increased gastrointestinal complaints, the tolerability of the lower dose underscores its suitability for broader outpatient use. Clinicians should monitor renal function, as modest creatinine elevations were observed, but these changes were clinically insignificant in the short term.

The broader implications extend to health systems grappling with the long‑term sequelae of the pandemic. With an estimated 6 % of COVID‑19 survivors developing PCC, scalable interventions are urgently needed. Creatine is inexpensive, widely available, and has a well‑established safety profile, making it an attractive candidate for larger, multicenter trials. Should future research confirm these pilot results, creatine could be incorporated into guideline‑driven care pathways, offering patients a tangible means to regain functional capacity and reduce the socioeconomic impact of long‑COVID fatigue.